References
- National Kidney Foundation. KDOQI Clinical practice guideline for diabetes and CKD. Am J Kidney Dis 2012;60:850-886. Available at: https://www.kidney.org/sites/default/files/docs/diabetes-ckd-update-2012.pdf
- International Diabetes Federation. IDF Diabetes Atlas. IDF; 2014
- de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532-9
- Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;9:529-50
- Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012;51:501-14
- Reilly JB, Berns JS. Selection and dosing of medications for management of diabetes in patients with advanced kidney disease. Sem Dialysis 2010;23:163-8
- Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther 2009;31:2608-17
- Lalau JD. Lactic acidosis induced by metformin: incidence, management and prevention. Drug Safety 2010;33:727-40
- Inzucchi SE, Lipska KJ, Mayo H, et al. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014;312:2668-75
- US Food Drug Administration. FDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. US Department of Health and Human Services;2016
- Penfornis A, Blickle JF, Fiquet B, et al. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. Vasc Health Risk Manag 2014;10:341-52
- Khanal A, Peterson GM, Castelino RL, et al. Potentially inappropriate prescribing of renally cleared drugs in elderly patients in community and aged care settings. Drugs Aging 2015;32:391-400
- Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med 2011;123:133-43
- Doody HK, Peterson GM, Watson D, et al. Retrospective evaluation of potentially inappropriate prescribing in hospitalized patients with renal impairment. Curr Med Res Opin 2015;31:525-35
- Chodick G, Heymann AD, Shalev V, et al. The epidemiology of diabetes in a large Israeli HMO. Eur J Epidemiol 2003;18:1143-6
- Ioannidis I. Diabetes treatment in patients with renal disease: is the landscape clear enough? World J Diabetes 2014;5:651-8
- Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes 2013;6:161-70
- Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-100
- Rigalleau V, Lasseur C, Perlemoine C, et al. Estimation of glomerular filtration rate in diabetic subjects: Cockcroft formula or modification of diet in renal disease study equation? Diabetes care 2005;28:838-43
- Spanopoulos D, Barrett B, Busse M, et al. Prescription of DPP-4 inhibitors to type 2 diabetes mellitus patients with renal impairment: a UK primary care experience. Clin Ther 2018;40:152-4
- Lamine F, Lalubin F, Pitteloud N, et al. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs. Swiss Med Wkly 2016;146:w14282
- Brown AL, Sainsbury CR, Fenelon C, et al. Dipeptidyl peptidase 4 inhibitors in routine clinical practice: experiences from a Scottish teaching hospital. Br J Diab 2014;14:134-7
- Huang H, Shetty S, Bauer E, et al. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease. Curr Med Res Opin 2018:1-7
- Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-67
- Webster AC, Nagler EV, Morton RL, et al. Chronic kidney disease. Lancet 2017;389:1238-52
- Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diab Care 2011;34:1431-7
- Pongwecharak J, Tengmeesri N, Malanusorn N, et al. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci 2009;31:481-6